ClinicalTrials.gg
CompletedNCT01118845Updated Jul 4, 2013Results posted

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Phase 2 interventional study of SyB L-0501 and Rituximab in Non-Hodgkin's Lymphoma, Lymphoma, Large Cell and Diffuse, Mantle Cell Lymphoma, Lymphoma, sponsored by SymBio Pharmaceuticals. Completed at 25 sites in 2 countries. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-07-04.

Sponsored by SymBio Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Non-randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 40 studies testing bendamustine in Lymphoma, Non-Hodgkin — none open to participants now, none under way, none of them phase 3. bendamustine · Lymphoma, Non-Hodgkin.

Enrollment
9th of 40
63 · median 38
Started
2010
with 9 others
Phase 2
19 of 40
none open now
Registered
18th of 40
by date
Lead sponsor
4 of 40
SymBio Pharmaceuticals

Among the 40 studies testing bendamustine in Lymphoma, Non-Hodgkin, this one is the 9th largest by enrollment, is one of 10 that started in 2010, is one of 19 in phase 2, and was the 18th registered.

Lymphoma, Non-Hodgkin

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

None of the 40 studies testing bendamustine in Lymphoma, Non-Hodgkin is open now. The open studies under Lymphoma, Non-Hodgkin, anywhere →

About bendamustine

bendamustine: first FDA approval 2008 (TREANDA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 242 Lymphoma, Non-Hodgkin studies recruiting now, 142 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing bendamustine in Lymphoma, Non-Hodgkin as a file.
02

Study summary

The purpose of this study is to determine the efficacy of SyB L-0501 in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Read the detailed description

Primary Objective is to determine the efficacy, as measured by overall response rate on the basis of Revised Response Criteria for Malignant Lymphoma, of SyB L-0501 at 120 mg/m\^2/day on day2 and 3 in combination with rituximab at 375 mg/m\^2 on day 1 of each 21-day cycle in patients with relapsed/refractory diffuse large B-cell lymphoma.

03

Conditions studied

  • Non-Hodgkin's Lymphoma
  • Lymphoma, Large Cell
  • Diffuse, Mantle Cell Lymphoma, Lymphoma
  • Follicular Lymphoma
  • Large B-Cell, Diffuse

Keywords

  • Non-Hodgkin's lymphoma
  • Lymphoma, Large B-Cell
  • Diffuse, Mantle cell lymphoma, Lymphoma
  • Follicular, Lymphoma
  • Large B-Cell, Diffuse
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with documented Cluster of differentiation 20 (CD20)-positive for lymphoma cells
  • Patients with
  • Patients with measurable lesions >1.5 cm in major axes
  • after 1 to 3 prior therapeutic treatments for diffuse large B-cell lymphoma.
  • Patients who are expected to survive for at least 3 months
  • Patients aged from 20 to 75 years at the time is obtained
  • Performance Status (P.S.) of 0 to 1 at initial administration of the study drug
  • Patients with adequately maintained organ functions
  • Patients capable of personally giving voluntary informed consent in writing to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Patients who have been without treatment for less than 3 weeks after prior treatment
  • Patients who can be candidates for peripheral blood stem cell transplantation at the discretion of the investigator.
  • Patients who received adequate prior treatments and did not respond to any of them.
  • Patients with central nervous system (CNS) involvement or patients with clinical symptoms suggestive of CNS involvement.
  • Patients with serious, active infections
  • Patients with serious complications
  • Patients with complications or medical history of serious cardiac disease
  • Patients with serious gastrointestinal symptoms
  • Patients with malignant pleural effusion, cardiac effusion, or ascites retention
  • Patients positive for surface (HBs) antigen, virus (HCV) antibody, or antibody
  • Patients with serious bleeding tendencies
  • Patients with a fever of 38.0°C or higher
  • Patients with, or confirmed in the past to have had, interstitial pneumonia, pulmonary fibrosis, or pulmonary emphysema
  • Patients with active multiple primary cancer or patients with a history of other malignant cancer within the past 5 years, except for basal cell cancer of the skin, squamous cell cancer, or cervical cancer in situ
  • Patients with, or confirmed in the past to have had, hemolytic anemia
  • Patients who received SyB L-0501 in the past
  • Patients who received cytokine preparation such as erythropoietin or granulocyte colony-stimulating factor (G-CSF) or blood transfusions within 2 weeks before the examination at registration for this study
  • Patients who received other products or unapproved medication within 3 months before registration in this study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    SyB L-0501

    Drug: SyB L-0501 · Drug: Rituximab

Interventions

  • The administration of SyB L-0501 at 120 mg/m\^2/day by intravenous infusion on day 2 and 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule. SyB L-0501 60 mg/m\^2, 90 mg/m\^2 or 120 mg/m\^2/day on Day 2 and Day 3 will be followed by 18 days of observation.

    Also known as: Bendamustine hydrochloride

  • The administration of rituximab at 375 mg/m\^2/day by intravenous infusion on day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.

06

What researchers measure

Primary outcomes

  1. The Overall Response Rate [Complete Response (CR) + Partial Response (PR)] Determined on the Basis of Revised Response Criteria for Malignant Lymphoma

    CR: Disappearance of all evidence of disease. PR: Regression of measurable disease and no new sites. For the criteria for CR, See Outcome measure 2 description. The criteria for PR is as below. Nodal Masses: more than 50% decrease in sum of the product of the perpendicular diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes 1. FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site 2. Variably FDG-avid or PET negative; regression on CT Spleen, Liver: more than 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified

    Time frame: up to 30 weeks

Secondary outcomes

  1. The Complete Response (CR) Rate Determined on the Basis of Revised Response Criteria for Malignant Lymphoma

    The criteria for CR is as below Nodal Masses: 1. fluorodeoxy glucose (FDG)-avid or positron emission tomography (PET) positive prior to therapy; mass of any size permitted if PET negative 2. Variably FDG-avid or PET negative; regression to normal size on computed tomography (CT) Spleen, Liver: Not palpable, nodules disappeared Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative

    Time frame: up to 30 weeks

  2. Progression Free Survival (PFS)

    PFS = day of the first PFS event - day of start of study treatment + 1 The definitions of PFS event are as below. 1. PD according to overall response on the basis of Revised Response Criteria for Malignant Lymphoma PD: Any new lesion or increase by ≥50% of previously involved sites from nadir. Nodal masses; Appearance of a new lesion(s) \>1.5 cm in any axis, ≥50% increase in SPD of more than one node, or ≥50% increase in longest diameter of a previously identified node \>1 cm in short axis. Lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. Spleen, Liver; ≥50% increase from nadir in the SPD of any previous lesions. Bone marrow; New or recurrent involvement 2. Disease progression during treatment period 3. Disease progression during follow up period 4. Start of treatment of new lesion 5. Occurrence of other multiple malignant tumors 6. Death

    Time frame: up to 30 weeks

  3. Number of Subjects With Adverse Event

    Time frame: up to 30 weeks

  4. Number of Adverse Events

    Time frame: up to 30 weeks

  5. Number of Subjects With Abnormality (Grade ≥3) in Laboratory Test Values

    Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using Common Terminology Criteria for Adverse Events (CTCAE). grade 1 : mild grade 2 : moderate grade 3 : severe grade 4 : life threatening or disabling grade 5 : death related to adverse event

    Time frame: up to 30 weeks

  6. Number of Subjects With Grade ≥3 Physical Examination Finding

    Time frame: up to 30 weeks

  7. Concomitant Medication Usage

    Time frame: up to 30 weeks

  8. The Maximum Concentration (Cmax) of Unchanged SyB L-0501 in Japan

    Time frame: Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle

  9. The Maximum Drug Concentration Time (Tmax) of Unchanged SyB L-0501 in Japan

    Time frame: Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle

  10. The Area Under the Curve (AUC) for Unchanged SyB L-0501 in Japan

    Time frame: Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle

  11. The Half-life Period (t1/2) of Unchanged SyB L-0501 in Japan

    Time frame: Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle

  12. The Maximum Concentration (Cmax) of Unchanged SyB L-0501 in Korea

    Time frame: Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle

  13. The Maximum Drug Concentration Time (Tmax) of Unchanged SyB L-0501 in Korea

    Time frame: Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle

  14. The Area Under the Curve (AUC) for Unchanged SyB L-0501 in Korea

    Time frame: Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle

  15. The Half-life Period (t1/2) of Unchanged SyB L-0501 in Korea

    Time frame: Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle

07

Results

Posted Jul 4, 2013

Participant flow

Participant flow — Overall Study
MilestoneSyB L-0501
Started59
Completed17
Not completed42

Outcome measures

PrimaryThe Overall Response Rate [Complete Response (CR) + Partial Response (PR)] Determined on the Basis of Revised Response Criteria for Malignant Lymphoma

CR: Disappearance of all evidence of disease. PR: Regression of measurable disease and no new sites. For the criteria for CR, See Outcome measure 2 description. The criteria for PR is as below. Nodal Masses: more than 50% decrease in sum of the product of the perpendicular diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes 1. FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site 2. Variably FDG-avid or PET negative; regression on CT Spleen, Liver: more than 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified

Time frame:
up to 30 weeks
Reported as:
Number · Percentage of Participants
The Overall Response Rate [Complete Response (CR) + Partial Response (PR)] Determined on the Basis of Revised Response Criteria for Malignant Lymphoma
Percentage of ParticipantsSyB L-0501
The Overall Response Rate [Complete Response (CR) + Partial Response (PR)] Determined on the Basis of Revised Response Criteria for Malignant Lymphoma62.7 (49.1 to 75.0)
SecondaryThe Complete Response (CR) Rate Determined on the Basis of Revised Response Criteria for Malignant Lymphoma

The criteria for CR is as below Nodal Masses: 1. fluorodeoxy glucose (FDG)-avid or positron emission tomography (PET) positive prior to therapy; mass of any size permitted if PET negative 2. Variably FDG-avid or PET negative; regression to normal size on computed tomography (CT) Spleen, Liver: Not palpable, nodules disappeared Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative

Time frame:
up to 30 weeks
Reported as:
Number · Percentage of participants
The Complete Response (CR) Rate Determined on the Basis of Revised Response Criteria for Malignant Lymphoma
Percentage of participantsSyB L-0501
The Complete Response (CR) Rate Determined on the Basis of Revised Response Criteria for Malignant Lymphoma37.3 (25.0 to 50.9)
SecondaryProgression Free Survival (PFS)

PFS = day of the first PFS event - day of start of study treatment + 1 The definitions of PFS event are as below. 1. PD according to overall response on the basis of Revised Response Criteria for Malignant Lymphoma PD: Any new lesion or increase by ≥50% of previously involved sites from nadir. Nodal masses; Appearance of a new lesion(s) \>1.5 cm in any axis, ≥50% increase in SPD of more than one node, or ≥50% increase in longest diameter of a previously identified node \>1 cm in short axis. Lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. Spleen, Liver; ≥50% increase from nadir in the SPD of any previous lesions. Bone marrow; New or recurrent involvement 2. Disease progression during treatment period 3. Disease progression during follow up period 4. Start of treatment of new lesion 5. Occurrence of other multiple malignant tumors 6. Death

Time frame:
up to 30 weeks
Reported as:
Median · Days
Progression Free Survival (PFS)
DaysSyB L-0501
Progression Free Survival (PFS)200.0 (109.0 to 410.0)
SecondaryNumber of Subjects With Adverse Event
Time frame:
up to 30 weeks
Reported as:
Number · Participants
Number of Subjects With Adverse Event
ParticipantsSyB L-0501
Subjects with adverse event59
Subjects with serious adverse event14
SecondaryNumber of Adverse Events
Time frame:
up to 30 weeks
Reported as:
Number · Events
Number of Adverse Events
EventsSyB L-0501
Adverse events1848
Serious adverse events23
SecondaryNumber of Subjects With Abnormality (Grade ≥3) in Laboratory Test Values

Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using Common Terminology Criteria for Adverse Events (CTCAE). grade 1 : mild grade 2 : moderate grade 3 : severe grade 4 : life threatening or disabling grade 5 : death related to adverse event

Time frame:
up to 30 weeks
Reported as:
Number · Participants
Number of Subjects With Abnormality (Grade ≥3) in Laboratory Test Values
ParticipantsSyB L-0501
Subjects with grade 3 abnormality2
Subjects with grade 4 abnormality54
SecondaryNumber of Subjects With Grade ≥3 Physical Examination Finding
Time frame:
up to 30 weeks
Reported as:
Number · Participants
Number of Subjects With Grade ≥3 Physical Examination Finding
ParticipantsSyB L-0501
Subjects with grade 3 Physical Findings1
Subjects with grade 4 Physical Findings22
SecondaryConcomitant Medication Usage
Time frame:
up to 30 weeks
Reported as:
Number · Participants
Concomitant Medication Usage
ParticipantsSyB L-0501
concomitant medications for adverse events58
concomitant medications for complications50
concomitant medications for supportive therapy59
concomitant medications for other reasons59
SecondaryThe Maximum Concentration (Cmax) of Unchanged SyB L-0501 in Japan
Time frame:
Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle
Reported as:
Mean · ng/mL
The Maximum Concentration (Cmax) of Unchanged SyB L-0501 in Japan
ng/mLSyB L-0501
The Maximum Concentration (Cmax) of Unchanged SyB L-0501 in Japan8365.82 ± 3522.73
SecondaryThe Maximum Drug Concentration Time (Tmax) of Unchanged SyB L-0501 in Japan
Time frame:
Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle
Reported as:
Median · hour
The Maximum Drug Concentration Time (Tmax) of Unchanged SyB L-0501 in Japan
hourSyB L-0501
The Maximum Drug Concentration Time (Tmax) of Unchanged SyB L-0501 in Japan1.0 ± 0.0
SecondaryThe Area Under the Curve (AUC) for Unchanged SyB L-0501 in Japan
Time frame:
Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle
Reported as:
Mean · ng・h/mL
The Area Under the Curve (AUC) for Unchanged SyB L-0501 in Japan
ng・h/mLSyB L-0501
The Area Under the Curve (AUC) for Unchanged SyB L-0501 in Japan10394.39 ± 5368.77
SecondaryThe Half-life Period (t1/2) of Unchanged SyB L-0501 in Japan
Time frame:
Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle
Reported as:
Median · hour
The Half-life Period (t1/2) of Unchanged SyB L-0501 in Japan
hourSyB L-0501
The Half-life Period (t1/2) of Unchanged SyB L-0501 in Japan0.39 ± 0.1
SecondaryThe Maximum Concentration (Cmax) of Unchanged SyB L-0501 in Korea
Time frame:
Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle
Reported as:
Mean · ng/mL
The Maximum Concentration (Cmax) of Unchanged SyB L-0501 in Korea
ng/mLSyB L-0501
The Maximum Concentration (Cmax) of Unchanged SyB L-0501 in Korea8095.99 ± 4339.74
SecondaryThe Maximum Drug Concentration Time (Tmax) of Unchanged SyB L-0501 in Korea
Time frame:
Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle
Reported as:
Median · hour
The Maximum Drug Concentration Time (Tmax) of Unchanged SyB L-0501 in Korea
hourSyB L-0501
The Maximum Drug Concentration Time (Tmax) of Unchanged SyB L-0501 in Korea0.9 ± 0.3
SecondaryThe Area Under the Curve (AUC) for Unchanged SyB L-0501 in Korea
Time frame:
Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle
Reported as:
Mean · ng・h/mL
The Area Under the Curve (AUC) for Unchanged SyB L-0501 in Korea
ng・h/mLSyB L-0501
The Area Under the Curve (AUC) for Unchanged SyB L-0501 in Korea9218.56 ± 6696.81
SecondaryThe Half-life Period (t1/2) of Unchanged SyB L-0501 in Korea
Time frame:
Prior to and 30 min after start of administration, and 0, 30, 60, 120 min after completion of administration on Day 2 of the 1st cycle
Reported as:
Median · hour
The Half-life Period (t1/2) of Unchanged SyB L-0501 in Korea
hourSyB L-0501
The Half-life Period (t1/2) of Unchanged SyB L-0501 in Korea0.48 ± 0.18

Adverse events

Collected over up to 30 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SyB L-0501—14/59 (23.7%)59/59 (100%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventSyB L-0501
Cytomegalovirus infectionInfections and infestations3/59
PneumoniaInfections and infestations3/59
ConstipationGastrointestinal disorders2/59
AstheniaGeneral disorders2/59
NeutropeniaBlood and lymphatic system disorders1/59
ThrombocytopeniaBlood and lymphatic system disorders1/59
DiarrhoeaGastrointestinal disorders1/59
DeathGeneral disorders1/59
Mucosal inflammationGeneral disorders1/59
InfectionInfections and infestations1/59
Most frequent other events
Showing 10 of 185
Most frequent other events
EventSyB L-0501
CD4 lymphocytes decreasedInvestigations41/59
White blood cell count decreasedInvestigations37/59
Neutrophil count decreasedInvestigations34/59
Lymphocyte count decreasedInvestigations33/59
AnaemiaBlood and lymphatic system disorders30/59
ConstipationGastrointestinal disorders29/59
White blood cell count increasedInvestigations27/59
Blood immunoglobulin G decreasedInvestigations26/59
Platelet count decreasedInvestigations26/59
Blood immunoglobulin M decreasedInvestigations25/59

Baseline characteristics

Age Continuous
Age Continuous(Year)SyB L-0501
Mean64.2 ± 9.2
Age, Customized
Age, Customized(Percentage of participants)SyB L-0501
20-29 years0.0
30-39 years1.7
40-49 years8.5
50-59 years16.9
60-69 years39.0
70-75 years33.9
Age, Customized
Age, Customized(Percentage of participants)SyB L-0501
<65 years37.3
≥65 years62.7
Sex/Gender, Customized
Sex/Gender, Customized(percentage of participants)SyB L-0501
Male42.4
Female57.6
Diagnosis of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Diagnosis of Relapsed/Refractory Diffuse Large B-Cell Lymphoma(percentage of participants)SyB L-0501
Number100.0
Clinical Stage (Ann Arbor staging)
Clinical Stage (Ann Arbor staging)(Percentage of participants)SyB L-0501
Stage I5.1
Stage I-E3.4
Stage II27.1
Stage II-E3.4
Stage III25.4
Stage III-S6.8
Stage III-E3.4
Stage III-SE0.0
Stage IV25.4
Unknown0.0
Systemic symptoms (B symptoms) (Ann Arbor staging)
Systemic symptoms (B symptoms) (Ann Arbor staging)(Percentage of participants)SyB L-0501
Asymptomatic86.4
Symptomatic13.6
Unknown0.0
Medical history of diffuse large B-cell lymphoma (DLBCL)
Medical history of diffuse large B-cell lymphoma (DLBCL)(Percentage of participants)SyB L-0501
No40.7
Yes59.3

20 further baseline measures are reported on the registry.

08

Study locations

25 sites
  • Nagoya, Aichi, Japan
  • Matsuyama, Ehime, Japan
  • Kurume, Fukuoka, Japan
  • Maebashi, Gunma, Japan
  • Sapporo, Hokkaido, Japan
  • Kanazawa, Ishikawa, Japan
  • Isehara, Kanagawa, Japan
  • Ninomaru, Kumamoto, Japan
  • Sendai, Miyagi, Japan
  • Kita-ku, Okayama, Japan
  • Kurashiki, Okayama, Japan
  • Hidaka, Saitama, Japan
  • Izumo, Shimane, Japan
  • Chuo-ku, Tokyo, Japan
  • Akita, Japan
  • Fukuoka, Japan
  • Kagoshima, Japan
  • Kyoto, Japan
  • Seo-gu, Busan, Korea, Republic of
  • Jung-gu, Daegu, Korea, Republic of
  • Goyang-si, Gyeonggi-do, Korea, Republic of
  • Hwasun-gun, Jeonnam, Korea, Republic of
  • Gangnam-gu, Seoul, Korea, Republic of
  • Seodaemun-gu, Seoul, Korea, Republic of
  • Songpa-gu, Seoul, Korea, Republic of
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2010
First posted
May 7, 2010
Start
Apr 2010
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results first posted
Jul 4, 2013
Last update
Jul 4, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 4, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01118845
First posted
May 7, 2010
Start date
Apr 2010
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Jul 4, 2013
Last update
Jul 4, 2013

Study contacts

Kensei Tobinai, MD, Ph D
study chair · National Cancer Center Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bendamustine · Rituximab

Start the discussion